The FDA approved Boehringer's nerandomilast, now Jascayd, as the first new U.S. treatment for idiopathic pulmonary fibrosis ...

Nerandomilast appears to reduce the risk of death in people with IPF and PPF, according to analyses of clinical trial data.

Columnist Sam Kirton's diagnostic journey was relatively short compared with that of other idiopathic pulmonary fibrosis (IPF) patients.

In her columns debut, Debbie Klein shares the story of her late husband Steve's idiopathic pulmonary fibrosis diagnosis.

For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.

GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. “The FVC data after 6 weeks ...

I’m at it again; I’m job hunting, or seeking employment, if you will. But this time, the search carries more weight. It’s not just about finding work; it’s about reclaiming a part of myself that I ...

Second in a series. Read part 1 about the foundation’s work of the past 25 years. During my interview with Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation (PFF), I was struck by ...

The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result ...

Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis ...